An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors

Table 2

Test of heterogeneity and publication bias.

		Test of heterogeneity			Publication bias
	No. of study	value	value		value (Begg’s)	value (Egger’s)
Risk ratio
All adverse events	47	205.9	<0.001	74.26	0.357	0.007
Serious adverse events	44	50.37	0.419	2.720	0.181	0.230
Diabetes-related adverse events	20	21.64	0.420	2.961	0.155	0.311
Neurocognitive and neurologic adverse events	19	15.72	0.676	<0.001	0.103	0.341
Event rate
Long-term all adverse events	13	227.7	<0.001	94.73	0.427	0.350
Long-term serious adverse events	13	583.6	<0.001	97.94	0.251	0.062
Long-term diabetes-related adverse events	10	353.4	<0.001	97.45	0.237	0.013
Long-term neurocognitive and neurologic adverse events	12	182.4	<0.001	93.97	0.269	0.409